Sabitlenmiş Tweet
Age is the primary risk factor for most cancers, but we devote far more resources to treating individual diseases than addressing the root cause.
English
Chris Patil
17.2K posts
Chris Patil
@DoNotGoGently
Biologist of aging. VP-Media at @bioagelabs. Producer and host of @bioagepodcast. Tweets, politics, & memes are my own. (he/him)
San Francisco Katılım Şubat 2009
1.2K Takip Edilen2.3K Takipçiler
Betrayal! Deception! Treachery!
Those ads are funny
(and the former meta ads executive who made them is good at his job. he had a lot of practice)
Here’s what’s not funny:
Calling “ads” a betrayal when your business model is selling paid subscriptions to companies.
ChatGPT has more free users in Texas than Claude (trademark) has globally.
Real betrayal isn’t ads. It’s control.
Anthropic thinks powerful AI should be tightly controlled in small rooms in San Francisco and Davos.
That its too DANGEROUS for you.
That the future should be built somewhere else, by someone who is smarter
We don’t believe that.
Every week, 300M+ people use ChatGPT to learn how to do something.
More than half of U.S. users say it helped them do something they once thought was impossible.
Free access creates agency.
When people have the tools, THEY decide what to build.
You can just build things.
English
@KarlPfleger @MartinBJensen notwithstanding this quibble, I agree with Martin on the importance of dedicating capital to techs that enable large-scale increase in healthy lifespan
English
Great reality check for longevity biohackers:
The effect sizes you seek aren't available on Earth today.
People who can afford anything legal or illegal end up living 4-8 years longer than average.
Fund the work of scaling and industrializing longevity science so it becomes possible to add decades of healthy life.
Alexey Strygin@strygah
I tracked every billionaire who died in the last decade. 389 deaths. $2.17 trillion in wealth. 6 helicopter crashes. Here's what I found.
English
Chris Patil retweetledi
We're pleased to share additional positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor — showing potential best-in-class hsCRP reduction in patients with elevated cardiovascular risk.
Read the release:
ir.bioagelabs.com/news-releases/…
Key findings from our first MAD cohort in obese participants with elevated hsCRP:
• Rapid and profound reduction in hsCRP, a widely used marker of inflammatory cardiovascular risk: 86% median reduction at Day 14
• 93% of participants achieved hsCRP levels < 2 mg/L, the clinical threshold for reduced cardiovascular risk
• Broad anti-inflammatory effects: Significant reductions in IL-6 and fibrinogen, key independent markers of cardiovascular risk
• Well tolerated: Favorable safety profile with no dose-limiting toxicities
Path forward: Full Phase 1 data, including additional multiple ascending dose (MAD) cohorts in participants with obesity and elevated hsCRP, anticipated 1H26
Phase 2a study on track to initiate 1H26, with readout anticipated by year-end
Aging biology in action: Chronic inflammation is now recognized as a major driver of cardiovascular disease—on par with cholesterol—yet it remains undertreated. NLRP3 is a key driver of age-related inflammation, and BioAge's discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. With the potential to deliver injectable-like inflammation reduction in a convenient oral therapy, BGE-102 could address a significant unmet need in cardiovascular risk management and beyond.
We look forward to sharing full Phase 1 results in the first half of this year!
English
Chris Patil retweetledi
What will it take to turn the science of aging into new medicines that benefit millions of people? BioAge CEO and co-founder @kpfortney sat down with @TIME magazine’s @dmosbergen for an in-depth conversation about why targeting the biology of aging could transform how we treat metabolic disease—and why the field is at an inflection point.
The interview, published in TIME’s “Future of Living” series, covers topics including:
• 🔬 BioAge’s human-first approach — With decades of health records and biological samples, we can study what's different about people who age well and work backward to find drug targets.
• 💊 BGE-102, our lead NLRP3 inhibitor — Now in Phase 1 clinical trials, this once-daily oral therapy targets the chronic inflammation that drives cardiovascular risk as we age.
• 🏃 Apelin and the biology of exercise — We're developing drugs that mimic the molecular benefits of physical activity, with potential to help maintain healthy body composition during aging and therapeutic weight loss.
• 🤝 Why Big Pharma is leaning in — Our collaborations with Novartis and Lilly reflect growing recognition that aging biology offers a path to preventative medicines that address root causes of chronic disease.
"I'm expecting a lot to happen in the next 5 to 10 years," Kristen says. "The growth in the field has been tremendous, so that really bodes well."
Read the full interview: time.com/collections/fu…
English
Chris Patil retweetledi
Why does ‘anti-aging’ hype sometimes drown out the best aging science? Why does Hollywood keep casting life-extension seekers as villains? And how can we educate the public about what the biology of aging makes possible?
Today at the 2025 Longevity Summit at @BuckInstitute, BioAge's VP-Media Chris Patil, PhD (@DoNotGoGently) is facilitating a conversation about the media narratives surrounding longevity science — and how we might tell them better.
Joining Chris on the panel will be:
- Zara Stone, Culture & Tech reporter at The San Francisco Standard
- Keith Comito, CEO & President, Lifespan Research Institute
- Gary J. Alan, Co-founder, ALSAE Foundation
English
One reason I've been resisting Gemini and sticking with Claude is the lack of consistent-context features like Projects. But I just had the thought that with Gemini 3 Pro under the hood and great RAG...is NotebookLM essentially Projects for Gemini?
English
Congratulations to the whole @bioagelabs team!
BioAge@bioagelabs
We're pleased to share positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor being developed for patients with cardiovascular risk factors. ➡️Read the release: globenewswire.com/news-release/2… Key findings: • Well tolerated across all SAD and MAD dose levels Convenient dosing: Pharmacokinetic profile supports once-daily oral administration • Robust target engagement: Achieved up to 98% suppression of IL-1β, a key upstream regulator of hsCRP and other inflammatory factors implicated in cardiovascular risk • High brain penetration, enabling targeting of both central and peripheral inflammation Path forward: • We’re expanding the Phase 1 trial with additional MAD cohorts in participants with obesity and elevated cardiovascular risk factors enabling evaluation of biomarkers including hsCRP — data anticipated in 1H26 • A Phase 2a POC study focused cardiovascular risk factors in patients with obesity is anticipated to initiate in 2H26, with readout by end of year Aging biology in action: NLRP3-driven inflammation is a hallmark of aging implicated in cardiovascular disease and metabolic dysfunction, and BioAge’s discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. As a brain-penetrant inhibitor with potential best-in-class properties, BGE-102 has the potential to address age-related inflammation—offering a promising approach to treating metabolic disease and reducing cardiovascular risk. We look forward to sharing additional data in 2026!
English
Looking forward to joining a panel on "Longevity in the Media" at the Longevity Summit next week!
BioAge@bioagelabs
We're excited to join @LongevityGL's fourth annual Longevity Summit, taking place next week December 9-10 at the @BuckInstitute. BioAge COO and co-founder @eric_k_morgen, MD will deliver a keynote, and VP-Media Chris Patil, PhD (@DoNotGoGently) will join a panel discussion on longevity in the media. We're also proud to sponsor this year's event. The Longevity Summit brings together the entire longevity ecosystem—entrepreneurs, biopharma companies, investors, researchers, and government—for two days of peer-to-peer learning focused on the business of longevity and the key areas of innovation needed to advance the field. We're honored to share the stage with so many of the leaders working to extend human healthspan. ➡️ Registration is still open: longevitygl.org/longevity-summ… We look forward to seeing you there!
English
Chris Patil retweetledi
The blockbuster GLP-1 drugs have revolutionized treatment of obesity and diabetes, but also have potential for unprecedented impact on overall healthspan. An editorial in @NatureBiotech asks: Could they be the first longevity medications?
They won’t be the last. Beyond GLP-1s, the editorial spotlights two promising strategies for treating chronic disease by targeting molecular mechanisms involved in human aging: blocking inflammaging by inhibiting the NLRP3 inflammasome, and activating exerkine signaling by activating the apelin receptor APJ.
BioAge’s pipeline covers both strategies — an APJ agonist program spanning both oral small molecules and long-acting biologics; and BGE-102, our oral brain-penetrant NLRP3 inhibitor with best-in-class potential, is currently in Phase 1 trials with initial data anticipated by year-end.
We're developing therapies that target the root biology of metabolic aging to treat and prevent chronic disease — and pioneering the next generation of longevity drugs.
Read the editorial: nature.com/articles/s4158…
English
Chris Patil retweetledi
.@WHO emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy.
WHO recommends that all women continue to follow advice of their doctors or health workers, who can help assess individual circumstances and recommend necessary medicines.
Any medicine should be used with caution during pregnancy, especially in the first three months, and in line with advice from health professionals.
The full WHO statement: bit.ly/47YsgwI
English
Chris Patil retweetledi
Longevity companies (correctly) redefining all perturbations of cell state as "partial reprogramming" in response to funding trends.
English
@NebraskaMegan Counterpoint: demonstrating that Dems can counter GOP moves like TX is an important motivation for GOP to come to the table on a national gerrymandering ban. Otherwise they just win 2026 and that’s the end of the republic.
English
The answer to rigging elections for republicans is not rigging elections for democrats.
We need to ban gerrymandering and have districts redrawn every ten years with the census - as they are now - by independent redistricting commissions. That’s it
English
This is not good either!!!!!!!!!!
philip lewis@Phil_Lewis_
LOS ANGELES (AP) — California Gov. Newsom calls for Nov. 4 special election on redistricting plan aimed at adding Democratic US House seats.
English
jesus @airtable is your marketing team paid by the volume of email they send
English
Had an absolute blast moderating this panel at the Bay Area Aging Meeting! 🧬
Six brilliant minds and one big question: how do we get longevity science out of the lab and into patients' lives?
As I say in the episode: hosting this podcast is an honor and a joy.
Translating Aging@BioAgePodcast
How can we translate cutting-edge geroscience into medicines that will benefit humanity? This week's special episode features a live panel from the 25th Bay Area Aging Meeting, where six leading voices across academia, industry, and publishing tackled the critical challenge of moving aging research from bench to bedside. Over a wide-ranging and lively conversation, panelists Janine Sengstack (Junevity), Saul Villeda (UCSF), Jodi Nunnari (Altos Labs), Sebastien Thuault (Nature Aging), Anne Brunet (Stanford), and Nir Barzilai (Einstein) shared their thoughts on the emerging research directions poised for clinical impact, the revolutionary tools enabling precision aging interventions, and the cultural shifts needed to prepare the next generation of translational aging biologists. From the prospects for cellular rejuvenation entering the clinic to the regulatory challenges of targeting aging as an indication, this unscripted discussion offers rare insights from a distinguished group of thought leaders into how the field's most promising discoveries will become tomorrow's therapies. 🎧 Apple: podcasts.apple.com/us/podcast/bio… Spotify: open.spotify.com/show/1AjX0G0C9…
English
Chris Patil retweetledi
We desperately need to take all the people in SF who talk about accelerating biology but have only ever done math or CS and have them do a six month rotation in a wet lab.
Chris J. Maddison@cjmaddison
“Finally, maybe this is controversial but ultimately progress in science is bottlenecked by real-world experiments.” If this is controversial in SF, we’re cooked.
English
Any Arc members able to hook me up with an invite to the Dia beta?
English